Should we move past erythropoietin-stimulating agent monotherapy in lower-risk myelodysplastic syndromes? Mozessohn L, Buckstein R. Haematologica 2025 Jun 26. doi: 10.3324/haematol.2025.288157.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Mozessohn L, Buckstein R. Should we move past erythropoietin-stimulating agent monotherapy in lower-risk myelodysplastic syndromes? Haematologica 2025 Jun 26. doi: 10.3324/haematol.2025.288157.
PMID: 40568724